NURS 5359 Exam 1 antipsychotic
medications Questions With Accurate
Answers 100% Guarantee Pass
1. A patient taking a typical antipsychotic develops severe extrapyramidal
symptoms. The provider considers switching to an atypical antipsychotic that
targets the 5HT2A receptor. What is the expected outcome of this switch?
A. The severity of the extrapyramidal symptoms will increase.
B. The extrapyramidal symptoms may be reduced due to the receptor's
antagonism.
C. The medication will have no effect on the extrapyramidal symptoms.
D. The switch will only address mood-related symptoms, not motor
symptoms.
✓ CORRECT ANSWER: B. The extrapyramidal symptoms may be reduced due
to the receptor's antagonism.
RATIONALE: Atypical antipsychotics that block 5HT2A receptors help stabilize
dopamine concentrations in the central nervous system, which can reduce
the motor side effects (EPS) commonly associated with typical
antipsychotics.
---
2. A nurse is reviewing the medication list for a patient prescribed
Lurasidone. The patient is also taking a strong CYP3A4 inducer. What is the
significance of this interaction?
,A. Strong CYP3A4 inducers have no impact on Lurasidone's effectiveness.
B. Strong CYP3A4 inducers enhance the effects of Lurasidone, leading to
increased side effects.
C. Strong CYP3A4 inducers can decrease the effectiveness of Lurasidone by
increasing its metabolism.
D. Strong CYP3A4 inducers are used to treat the side effects of Lurasidone.
✓ CORRECT ANSWER: C. Strong CYP3A4 inducers can decrease the
effectiveness of Lurasidone by increasing its metabolism.
RATIONALE: Lurasidone is metabolized by CYP3A4. Inducers increase the
metabolism of the drug, lowering its plasma concentration and potentially
reducing its therapeutic efficacy.
---
3. A patient prescribed deutetrabenazine (Austedo) should be monitored for
which serious adverse effect based on the black box warning?
A. Patients can stop taking the medication if they experience side effects.
B. Patients prescribed deutetrabenazine should be monitored for signs of
depression and suicidal thoughts.
C. Patients should increase their dosage if they feel depressed.
D. Patients do not need any special monitoring while on this medication.
✓ CORRECT ANSWER: B. Patients prescribed deutetrabenazine should be
monitored for signs of depression and suicidal thoughts.
RATIONALE: The black box warning for deutetrabenazine explicitly highlights
the risk of depression and suicidal thoughts, requiring close monitoring.
,---
4. Serotonin (5HT) is a neurotransmitter associated with mood, sleep, and
psychosis. A unique aspect of second-generation antipsychotics is their
ability to block 5HT2A receptors. What is the effect of this inhibition?
A. Induces anxiety
B. Stabilizes dopamine concentrations in the CNS
C. Causes hallucinations
D. Reduces platelet function
✓ CORRECT ANSWER: B. Stabilizes dopamine concentrations in the CNS
RATIONALE: Blocking 5HT2A receptors modulates dopamine release in
specific brain regions, stabilizing dopamine concentrations and reducing the
risk of motor side effects compared to pure D2 blockade.
---
5. Which antipsychotic medications are included in the 'Pines' category?
A. Haloperidol and Chlorpromazine
B. Ziprasidone and Lurasidone
C. Olanzapine and Quetiapine
D. Risperidone and Aripiprazole
✓ CORRECT ANSWER: C. Olanzapine and Quetiapine
, RATIONALE: The 'Pines' category is a mnemonic for atypical antipsychotics
ending in "-pine," specifically Olanzapine (Zyprexa) and Quetiapine
(Seroquel).
---
6. Which group of atypical antipsychotics would be expected to have the
lowest risk of EPS and the highest risk of weight gain and sedation?
A. dones
B. pips/rip
C. pines
D. pras
✓ CORRECT ANSWER: C. pines
RATIONALE: The "pines" (Olanzapine, Quetiapine) are known for having a
very low risk of extrapyramidal symptoms but a high risk of metabolic side
effects like weight gain and sedation.
---
7. Describe the impact of D2 receptor blockade on the nigrostriatal pathway
and its potential consequences.
A. D2 receptor blockade increases serotonin levels, reducing motor side
effects.
medications Questions With Accurate
Answers 100% Guarantee Pass
1. A patient taking a typical antipsychotic develops severe extrapyramidal
symptoms. The provider considers switching to an atypical antipsychotic that
targets the 5HT2A receptor. What is the expected outcome of this switch?
A. The severity of the extrapyramidal symptoms will increase.
B. The extrapyramidal symptoms may be reduced due to the receptor's
antagonism.
C. The medication will have no effect on the extrapyramidal symptoms.
D. The switch will only address mood-related symptoms, not motor
symptoms.
✓ CORRECT ANSWER: B. The extrapyramidal symptoms may be reduced due
to the receptor's antagonism.
RATIONALE: Atypical antipsychotics that block 5HT2A receptors help stabilize
dopamine concentrations in the central nervous system, which can reduce
the motor side effects (EPS) commonly associated with typical
antipsychotics.
---
2. A nurse is reviewing the medication list for a patient prescribed
Lurasidone. The patient is also taking a strong CYP3A4 inducer. What is the
significance of this interaction?
,A. Strong CYP3A4 inducers have no impact on Lurasidone's effectiveness.
B. Strong CYP3A4 inducers enhance the effects of Lurasidone, leading to
increased side effects.
C. Strong CYP3A4 inducers can decrease the effectiveness of Lurasidone by
increasing its metabolism.
D. Strong CYP3A4 inducers are used to treat the side effects of Lurasidone.
✓ CORRECT ANSWER: C. Strong CYP3A4 inducers can decrease the
effectiveness of Lurasidone by increasing its metabolism.
RATIONALE: Lurasidone is metabolized by CYP3A4. Inducers increase the
metabolism of the drug, lowering its plasma concentration and potentially
reducing its therapeutic efficacy.
---
3. A patient prescribed deutetrabenazine (Austedo) should be monitored for
which serious adverse effect based on the black box warning?
A. Patients can stop taking the medication if they experience side effects.
B. Patients prescribed deutetrabenazine should be monitored for signs of
depression and suicidal thoughts.
C. Patients should increase their dosage if they feel depressed.
D. Patients do not need any special monitoring while on this medication.
✓ CORRECT ANSWER: B. Patients prescribed deutetrabenazine should be
monitored for signs of depression and suicidal thoughts.
RATIONALE: The black box warning for deutetrabenazine explicitly highlights
the risk of depression and suicidal thoughts, requiring close monitoring.
,---
4. Serotonin (5HT) is a neurotransmitter associated with mood, sleep, and
psychosis. A unique aspect of second-generation antipsychotics is their
ability to block 5HT2A receptors. What is the effect of this inhibition?
A. Induces anxiety
B. Stabilizes dopamine concentrations in the CNS
C. Causes hallucinations
D. Reduces platelet function
✓ CORRECT ANSWER: B. Stabilizes dopamine concentrations in the CNS
RATIONALE: Blocking 5HT2A receptors modulates dopamine release in
specific brain regions, stabilizing dopamine concentrations and reducing the
risk of motor side effects compared to pure D2 blockade.
---
5. Which antipsychotic medications are included in the 'Pines' category?
A. Haloperidol and Chlorpromazine
B. Ziprasidone and Lurasidone
C. Olanzapine and Quetiapine
D. Risperidone and Aripiprazole
✓ CORRECT ANSWER: C. Olanzapine and Quetiapine
, RATIONALE: The 'Pines' category is a mnemonic for atypical antipsychotics
ending in "-pine," specifically Olanzapine (Zyprexa) and Quetiapine
(Seroquel).
---
6. Which group of atypical antipsychotics would be expected to have the
lowest risk of EPS and the highest risk of weight gain and sedation?
A. dones
B. pips/rip
C. pines
D. pras
✓ CORRECT ANSWER: C. pines
RATIONALE: The "pines" (Olanzapine, Quetiapine) are known for having a
very low risk of extrapyramidal symptoms but a high risk of metabolic side
effects like weight gain and sedation.
---
7. Describe the impact of D2 receptor blockade on the nigrostriatal pathway
and its potential consequences.
A. D2 receptor blockade increases serotonin levels, reducing motor side
effects.
